To All:

<https://docs.google.com/document/d/1tgRsPmHp66O1iIKRMZvfcajtIvfz85J7dQf6ShfWy7I/edit>

11:51 AM

Bruce Bray (to All):

<https://clinicaltrials.gov/ct2/results?cond=covid&term=hydroxychloroquine&cntry=&state=&city=&dist=&Search=Search>

11:53 AM

Jane Shellum (to All):

for the hydrochloroquine question - one example: <https://www.med.umich.edu/asp/pdf/adult_guidelines/COVID-19-treatment.pdf>

11:54 AM

Bruce Bray (to All):

for decontam at hospital level: <https://www.sages.org/n-95-re-use-instructions/>

11:55 AM

MIchael Cesino (to All):

I'm thinking what about use cases from the employer's (the business) in having to deal with COVID-19?

11:56 AM

Bruce Bray (to All):

<https://www.nebraskamed.com/sites/default/files/documents/covid-19/n-95-decon-process.pdf>

11:57 AM

Jane Shellum (to All):

<https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html>

# Jane Shellum (to All):

<https://www.nejm.org/doi/full/10.1056/NEJMsr2005760>

# Jane Shellum (to All):

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137402/>

# Bruce Bray (to All):

<https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19>